The numbers behind America's mental health crisis are not new. What is new is a growing conviction among founders and investors that AI can do something the existing system hasn't managed to: actually close the gap.

John Zhao is one of them. His two-year-old New York startup, Blossom Health, has just closed a $20 million funding round led by venture firm Headline to expand its AI-powered psychiatry platform across the United States. The raise also drew participation from Village Global, TA Ventures, Operator Partners, and Correlation Ventures. Headline co-founder Mathias Schilling will join Blossom's board as part of the deal.

"Mental health is the singular most important public health crisis in America," Zhao said. "Tens of millions of Americans are suffering because of an acute shortage in psychiatric care. By productizing AI to supercharge psychiatrists, Blossom is finally making psychiatry affordable and attainable for every American in need."

It's a bold claim. But Zhao has spent enough time inside the healthcare industry to believe the problem is structural and that the right product can do what years of mental health apps and virtual therapy platforms have failed to.

The problem with the current model

Mental health care in America doesn't just have a supply problem. It has a design problem.

The standard model an appointment, a gap of weeks, another appointment creates blind spots that can be dangerous. Patients deteriorate between sessions. Clinicians work with incomplete pictures. Practices are weighed down by administrative overhead that limits how many patients they can actually see. And the psychiatrists who could help the most are often the hardest to access and the most expensive to visit.

Blossom was built around the belief that AI can fix all three at once.

What Blossom actually does

Blossom describes itself as an AI-native psychiatry provider essentially a virtual clinic built around what it calls an all-in-one AI copilot for clinicians.

For psychiatrists, that means AI-assisted diagnosis, treatment planning, and medication selection, paired with automated tools that handle the administrative layer: billing, scheduling, and insurance coordination. The goal is to remove the operational drag that typically stops mental health practices from scaling, so clinicians can spend more of their time on patients and less on paperwork.

For patients, the platform works differently. Rather than leaving people in the silence between sessions, Blossom uses AI agents to check in regularly gathering the kind of ongoing context that helps clinicians spot problems before they escalate. Zhao described the experience in an interview with Fortune as being akin to a patient texting a therapist.

The access piece matters too. Blossom accepts major commercial insurance, with an average copay of around $22. Many patients can be seen in under 48 hours, often same-day a timeline that would be unrecognizable to anyone who has tried to book a psychiatric appointment through traditional channels.

Early traction and a clinical-first approach

The startup says its model is already finding ground. Blossom reports that hundreds of clinicians are currently using the platform across multiple states, collectively treating more than 10,000 patients.

Zhao brings a relevant mix of healthcare and scaling experience to the role. Before founding Blossom, he worked at Athelas and at EverQuote, where he was part of the team that helped grow the business through its IPO. At Blossom, he has made clinical oversight central to how the product is built a clinical director and network of practicing clinicians are involved in piloting features before any broader rollout.

It's a deliberate choice in a space where the stakes of moving too fast are unusually high.

What comes next

The $20 million will go toward scaling Blossom from its current base of hundreds of clinicians and tens of thousands of patients to a national footprint expanding access state by state while continuing to develop the AI capabilities at the core of the platform.

Mental health apps have promised transformation before and largely underdelivered. What makes Blossom's bet different is its focus not on replacing clinical care, but on making it possible at a scale the existing system has never reached.

Whether the platform can deliver on that promise nationally remains to be seen. But the early numbers, and the investor conviction behind them, suggest the model is at least pointing in the right direction.